Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196429 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01196429: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01196429 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196429, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial studies how well temsirolimus, carboplatin, and paclitaxel as first-line therapy works in treating patients with newly diagnosed stage III-IV clear cell ovarian cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus with combination chemotherapy may be an effective treatment for ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01196429
The ClinicalTrials.gov registry entry for NCT01196429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01196429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01196429 about?
NCT01196429 is a clinical study titled "Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer". This phase II trial studies how well temsirolimus, carboplatin, and paclitaxel as first-line therapy works in treating patients with newly diagnosed stage III-IV clear cell ovarian cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs u...
What is the current status of trial NCT01196429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-08. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01196429?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01196429?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.